We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

Sandbox Reserved 712

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(→'''Description''')
(→'''Description''')
Line 13: Line 13:
Because of its importance for the life-cycle of the retrovirus, HIV-PR are the major target for anti-HIV treatment.
Because of its importance for the life-cycle of the retrovirus, HIV-PR are the major target for anti-HIV treatment.
-
HIV protease inhibitors are the most potent agens used in anti-HIV treatment. However it occurs that HIV-PR develops a resistance to the inhibitor. [[(2)]]
+
HIV protease inhibitors are the most potent agens used in anti-HIV treatment. However it occurs that HIV-PR develop a resistance to the inhibitor. [[(2)]]
 +
 
 +
3ggu (also PR#DRV5#)
== '''Activity''' ==
== '''Activity''' ==

Revision as of 12:40, 27 December 2012

Template:Sandbox ESBS 2012

3ggu

Drag the structure with the mouse to rotate

Contents

Description

3ggu is a drug resistant HIV protease. Shown is a patient's variant in complex with darunavir.

HIV proteases (PR) are essential for the functioning of the retrovirus that causes AIDS. HIV needs active proteases to process Gag & Gap - Polymerase polyprotein precursors into mature structural proteins and replicative enzymes.

HIV proteases contain a highly conserved region Asp - Thr - Gly (Asp25, Thr26 and Gly27), with the aspartic residue beeing the active site in the aspartyl protease.(1)

Because of its importance for the life-cycle of the retrovirus, HIV-PR are the major target for anti-HIV treatment. HIV protease inhibitors are the most potent agens used in anti-HIV treatment. However it occurs that HIV-PR develop a resistance to the inhibitor. (2)

3ggu (also PR#DRV5#)

Activity

Structure

Applications

External Resources

References

(1) Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. F. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.

(2) Watkins T, Resch W, Irlbeck D, Swanstrom R (February 2003). "Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors". Antimicrob. Agents Chemother. 47 (2): 759–69. doi:10.1128/AAC.47.2.759-769.2003. PMC 151730. PMID 12543689.

Contributors

Julia Baaske, Angelika Wackerl

Retrieved from "http://52.214.119.220/wiki/index.php/Sandbox_Reserved_712"
Personal tools